Sharekhan's research report on Ipca Laboratories
Strong growth outlook, growth across all business verticals to lead to better profitability. Resolution of USFDA hurdles could provide further upside with the potential for upgrade of earnings estimates. We expect the company to report sales/profit CAGR of 19%/32% over FY2019-FY2021.
Outlook
We maintain our Buy rating on IPCA with revised PT of Rs. 1,220. Ipca reported impressive performance for Q2FY2020 with results ahead of estimates.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
Read More
